Adult Surviving Sepis Campaign Guidelines (Hour-1 Bundle) Children's Surviving Sepsis Campaign Guidelines
Adult ICU Liberation Guidelines and Bundle (A-F)
Management of Adults with COVID-19
Log In
Forgot username? Forgot password? New User? Sign Up Free
SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.
Live webcasts address the latest issues in critical care with the opportunity to engage thought leaders in discussion.
The Society of Critical Care Medicine's (SCCM) webcasts tackle late-breaking issues and the latest research. Attendees can attend from the convenience of their home or office with a live format that allows for lively discussion and access to thought leaders.
Missed a webcast or a live meeting? Recordings from select SCCM meetings and activities are available On Demand. Browse the list of On Demand Prodcuts.
The Critical Care for Non-ICU Clinicians: Expert Panel Series Webcasts engages a panel of critical care experts who will address questions from non-ICU clinicians caring for critically ill patients during the COVID-19 pandemic. Previous recorded webcasts from this special series are available free of charge.
Webcast COVID-19
A primer in documentation and billing for critical care services, this webcast is an essential update for critical care providers. Faculty will review key recommendations for coding and supportive documentation, including those changes due to the COVID-19 pandemic, such as telehealth visits.
Learn More
Webcast None
Should you consider updating your clinical practice related to targeted temperature management (TTM) after cardiac arrest? The TTM1 Trial results were published in 2013. At the time, this was the largest randomized clinical trial evaluating the use of TTM in survivors of cardiac arrest. Recently, results from the TTM2 trial were published, which supersede the TTM1 Trial results with new and potentially practice-changing data. Current clinical practice that follows the results of the TTM1 trial should now be reviewed in light of new information from the TTM2 trial.
Disclaimer